Get the Stockscreener App
17.36
2.66%
0.45
Pre-market:
17.70
0.34
+1.96%
Adaptive Biotechnologies Corp stock is traded at $17.36, with a volume of 1.91M.
It is up +2.66% in the last 24 hours and up +16.04% over the past month.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
See More
Previous Close:
$16.91
Open:
$16.9
24h Volume:
1.91M
Relative Volume:
0.98
Market Cap:
$2.64B
Revenue:
$205.22M
Net Income/Loss:
$-121.24M
P/E Ratio:
-21.32
EPS:
-0.8141
Net Cash Flow:
$-82.81M
1W Performance:
+0.81%
1M Performance:
+16.04%
6M Performance:
+135.87%
1Y Performance:
+258.68%
1-Day Range:
$16.81
$17.76
1-Week Range:
$16.59
$17.76
52-Week Range:
$4.27
$17.89
Adaptive Biotechnologies Corp Stock (ADPT) Company Profile
Name
Adaptive Biotechnologies Corp
Sector
Industry
Phone
206-659-0067
Address
1165 EASTLAKE AVE E, SEATTLE, WA
Compare ADPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADPT
Adaptive Biotechnologies Corp
|
17.36 | 2.57B | 205.22M | -121.24M | -82.81M | -0.8141 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-30-25 | Initiated | Guggenheim | Buy |
| Jun-18-25 | Initiated | Craig Hallum | Buy |
| Mar-21-25 | Upgrade | Goldman | Neutral → Buy |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Dec-21-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-25-22 | Initiated | Credit Suisse | Underperform |
| Jun-03-22 | Initiated | Piper Sandler | Neutral |
| Feb-16-22 | Reiterated | BTIG Research | Buy |
| Feb-16-22 | Reiterated | BofA Securities | Buy |
| Feb-16-22 | Reiterated | Goldman | Neutral |
| Feb-16-22 | Reiterated | JP Morgan | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Mar-03-21 | Downgrade | Goldman | Buy → Neutral |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-03-20 | Initiated | Goldman | Buy |
| Jul-23-19 | Initiated | BTIG Research | Buy |
| Jul-22-19 | Initiated | BofA/Merrill | Buy |
| Jul-22-19 | Initiated | Cowen | Outperform |
| Jul-22-19 | Initiated | Goldman | Neutral |
| Jul-22-19 | Initiated | Guggenheim | Buy |
| Jul-22-19 | Initiated | William Blair | Outperform |
View All
Adaptive Biotechnologies Corp Stock (ADPT) Latest News
Can technical indicators confirm Adaptive Biotechnologies Corporation’s reversalJuly 2025 Update & AI Forecast Swing Trade Picks - newser.com
Why Adaptive Biotechnologies Corporation stock could benefit from AI revolutionPortfolio Performance Report & Long Hold Capital Preservation Plans - newser.com
Using Ichimoku Cloud for Adaptive Biotechnologies Corporation technicalsWeekly Trade Recap & Free Community Consensus Stock Picks - newser.com
What catalysts could drive Adaptive Biotechnologies Corporation stock higherTake Profit & Daily Profit Focused Stock Screening - newser.com
Can Adaptive Biotechnologies Corporation (1HM) stock expand revenue streamsVolume Spike & Verified Chart Pattern Signals - newser.com
How New Developments Are Shaping Analyst Views on Adaptive Biotechnologies’ Future - Yahoo! Finance Canada
How Adaptive Biotechnologies Corporation stock reacts to oil pricesJuly 2025 PostEarnings & Reliable Momentum Entry Alerts - newser.com
How Adaptive Biotechnologies Corporation stock compares to industry benchmarksQuarterly Investment Review & AI Forecasted Stock Moves - newser.com
How Adaptive Biotechnologies Corporation stock performs in high volatility marketsPortfolio Performance Report & Consistent Return Investment Signals - newser.com
Does Adaptive Biotechnologies Corporation fit your quant trading modelPortfolio Gains Summary & Reliable Intraday Trade Alerts - newser.com
Cwm LLC Sells 1,487 Shares of Adaptive Biotechnologies Corporation $ADPT - Defense World
Adaptive Biotechnologies (ADPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Yahoo Finance
How Adaptive Biotechnologies Corporation stock trades during market volatilityTrade Signal Summary & Daily Chart Pattern Signal Reports - newser.com
Adaptive Biotechnologies2025 Funding Rounds & List of Investors - Tracxn
Adaptive Biotechnologies (ADPT) Price Target Increased by 17.35% to 16.76 - Nasdaq
What dividend safety score for Adaptive Biotechnologies Corporation stockJuly 2025 Drop Watch & AI Optimized Trading Strategy Guides - newser.com
Technical signs of recovery in Adaptive Biotechnologies Corporation2025 Market Trends & Verified Entry Point Detection - newser.com
Is Adaptive Biotechnologies Corporation stock supported by innovation pipelineGap Down & Comprehensive Market Scan Insights - newser.com
Heatmap analysis for Adaptive Biotechnologies Corporation and competitorsBuy Signal & Expert Approved Trade Ideas - newser.com
Is Adaptive Biotechnologies Corporation stock a contrarian buyBear Alert & Community Consensus Picks - newser.com
How Adaptive Biotechnologies Corporation (1HM) stock performs during market turbulenceTrade Entry Summary & Community Verified Watchlist Alerts - newser.com
Will Adaptive Biotechnologies Corporation stock benefit from upcoming earnings reportsPortfolio Gains Summary & Growth Focused Entry Point Reports - newser.com
Exit strategy if you’re trapped in Adaptive Biotechnologies CorporationPortfolio Risk Summary & Real-Time Volume Trigger Notifications - newser.com
Adaptive Biotechnologies Corp Stock (ADPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):